2007 in oncology

The approvals rows on treatment records: region, year and indication.

• 20075-Aminolevulinic acid (oral, for glioma surgery) approved in EU

  Visualisation of malignant tissue during surgery for WHO grade III-IV glioma

• 2007Dexrazoxane approved in US

  Anthracycline extravasation (Totect)

• 2007Epoetin alfa approved in EU

  First epoetin alfa biosimilars (Binocrit, Abseamed, Epoetin alfa Hexal) including chemotherapy-induced anaemia

• 2007Erlotinib approved in EU

  Metastatic pancreatic cancer with gemcitabine (Tarceva product information: factors associated with prolonged survival should be taken into account when prescribing; 100 mg daily)...

• 2007HPV bivalent vaccine (types 16 and 18) approved in EU

  Prevention of premalignant cervical lesions and cervical cancer caused by HPV 16 and 18 from age 9 (Cervarix); anal lesions added later

• 2007Ixabepilone approved in US

  Metastatic or locally advanced breast cancer after anthracycline and taxane (with capecitabine) or after anthracycline, taxane and capecitabine (monotherapy)

• 2007Lapatinib approved in US

  HER2+ advanced breast cancer with capecitabine after trastuzumab

• 2007MammaPrint (70-gene signature) approved in US

  FDA 510(k) clearance for recurrence risk in early breast cancer

• 2007Nelarabine approved in EU

  T-ALL and T-LBL after at least two regimens (Atriance)

• 2007Nilotinib approved in EU

  Ph+ CML

• 2007Nilotinib approved in US

  Ph+ CML, chronic or accelerated phase, resistant/intolerant to imatinib

• 2007Panitumumab approved in EU

  Metastatic colorectal cancer; RAS wild-type from 2013. Vectibix marketing authorisation issued 3 December 2007.

• 2007Raloxifene approved in US

  Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk

• 2007Sorafenib approved in US

  Unresectable HCC

• 2007Temsirolimus approved in EU

  Advanced RCC (poor risk); relapsed/refractory mantle cell lymphoma added 2009

• 2007Temsirolimus approved in US

  Advanced renal cell carcinoma

• 2007Topotecan approved in US

  Relapsed SCLC (oral)

• 2007Trabectedin approved in EU

  Advanced soft-tissue sarcoma after anthracycline/ifosfamide

The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.

• 16 November 2007Sorafenib: approval (US)

  Unresectable HCC on SHARP

The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.

• 2007Abigail Alliance v. von Eschenbach (2007)

  United States, court ruling.

The year reported on trial records, with the headline result the record gives.

• 2007EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancer reported

  Symptomatic brain metastases at 1 year 14.6% vs 40.4%; 1-year survival 27.1% vs 13.3%.

  Small-cell lung cancerExtensive-stage small-cell lung cancer
• 2007NCIC CO.17 reported

  Overall survival hazard ratio 0.77 (95% CI 0.64 to 0.92, p=0.005) against best supportive care alone; benefit confined to KRAS wild-type tumours.

  Colorectal cancerCetuximab
• 2007Photodynamic therapy against surgery for nodular basal cell carcinoma reported

  Five-year recurrence 14 per cent after methyl aminolevulinate photodynamic therapy against 4 per cent after excision (sustained complete response 76 against 96 per cent, p=0.01), w...

  Basal cell carcinomaSkin cancer (all types)Methyl aminolevulinate
• 2007QUASAR reported

  Relative risk of death 0.82 (0.70 to 0.95, p = 0.008) and of recurrence 0.78 (0.67 to 0.91, p = 0.001) with adjuvant fluorouracil and folinic acid; an absolute five-year survival g...

  Colorectal cancerColon cancer (adenocarcinoma of the colon)Fluorouracil (5-FU)Leucovorin (folinic acid)
• 2007WHEL (Women's Healthy Eating and Living) reported

  Breast cancer events 16.7% vs 16.9%; no effect on recurrence or mortality despite large dietary change.

  HR-positive / HER2-negative breast cancerTriple-negative breast cancer (TNBC)

The publication year on key paper records.

• 2007A randomized clinical trial of a brief hypnosis intervention to control side effects in breast surgery patients

  Montgomery GH, Bovbjerg DH, Schnur JB, et al. JNCI: Journal of the National Cancer Institute.

• 2007Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)

  Quasar Collaborative Group, Gray R, Barnwell J, et al. The Lancet.

• 2007Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

  Oettle H, Post S, Neuhaus P, et al. JAMA.

• 2007Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

  Hillmen P, Skotnicki AB, Robak T, et al. Journal of Clinical Oncology.

• 2007Aneuploidy acts both oncogenically and as a tumor suppressor

  Weaver BA, Silk AD, Montagna C, et al. Cancer Cell.

• 2007BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

  Xing M. Endocrine reviews.

• 2007Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-neg...

  Bauer KR, Brown M, Cress RD, et al. Cancer.

• 2007Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial

  Sankaranarayanan R, Esmy PO, Rajkumar R, et al. The Lancet.

• 2007Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer

  Oba K, Teramukai S, Kobayashi M, et al. Cancer immunology, immunotherapy.

• 2007Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia

  Dewey A, Baughan C, Dean T, et al. The Cochrane database of systematic reviews.

• 2007Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

  Soda M, Choi YL, Enomoto M, et al. Nature.

• 2007Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resection

  Pawlik TM, Gleisner AL, Vigano L, et al. Journal of Gastrointestinal Surgery.

• 2007Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and...

  Pierce JP, Natarajan L, Caan BJ, et al. JAMA.

• 2007Interfant-99: a treatment protocol for infants under one year with acute lymphoblastic leukaemia

  Pieters R, Schrappe M, De Lorenzo P, et al. The Lancet.

• 2007Jemal 2007: Cancer statistics, 2007

  Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. CA: A Cancer Journal for Clinicians.

• 2007Kelly and Russell 2007: a century of trying to treat cancer with viruses, and why it kept stopping

  Kelly E, Russell SJ. Molecular Therapy.

• 2007Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

  Dimopoulos M, Spencer A, Attal M, et al. New England Journal of Medicine.

• 2007Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy

  Symmans WF, Peintinger F, Hatzis C, et al. Journal of Clinical Oncology.

• 2007MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

  Engelman JA, Zejnullahu K, Mitsudomi T, et al. Science.

• 2007Prophylactic cranial irradiation in extensive small-cell lung cancer

  Slotman B, Faivre-Finn C, Kramer G, et al. New England Journal of Medicine.

• 2007Revisions to the staging and classification of mycosis fungoides and Sezary syndrome (ISCL/EORTC)

  Olsen E, Vonderheid E, Pimpinelli N, et al. Blood.

• 2007Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

  Levine RL, Pardanani A, Tefferi A, et al. Nature Reviews Cancer.

• 2007Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

  Goonetilleke KS, Siriwardena AK. European Journal of Surgical Oncology.

• 2007The spindle-assembly checkpoint in space and time

  Musacchio A, Salmon ED. Nature reviews. Molecular cell biology.

• 2007Triple-negative breast cancer: clinical features and patterns of recurrence

  Dent R, Trudeau M, Pritchard KI, et al. Clinical Cancer Research.

The history entries editors wrote on cancer records: the dated turning points of each disease.

• 2007'Triple-negative' enters clinical vocabulary

  Triple-negative breast cancer (TNBC). Defined by absence of ER, PR, HER2; recognised as the subtype with the fewest treatment options, which set the research agenda that followed.

• 2007Adjuvant mitotane associated with longer recurrence-free survival (Terzolo, NEJM)

  Adrenocortical carcinoma

  Mitotane
• 2007Cladribine reported as active in advanced mastocytosis

  Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)

  Cladribine
• 2007CONKO-001: adjuvant gemcitabine after resection lengthens disease-free survival

  Resectable pancreatic ductal adenocarcinoma

  Gemcitabine
• 2007CONKO-001: adjuvant gemcitabine doubles disease-free survival

  Pancreatic ductal adenocarcinoma. 368 patients; 13.4 versus 6.9 months.

  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialCONKO-001
• 2007EML4-ALK fusion discovered

  Non-small-cell lung cancer. Soda et al.; crizotinib approved 2011.

  ALK
• 2007EML4-ALK fusion discovered in lung cancer (Soda and Mano, Japan)

  ALK-positive non-small-cell lung cancer

  ALKGene fusion
• 2007EML4-ALK: the second driver

  Lung cancer (all types). A small inversion on chromosome 2p, found in 5 of 75 tumours, transformed fibroblasts.

  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerAnaplastic lymphoma kinase inhibition in non-small-cell lung cancer
• 2007Fallopian tube fimbria identified as the origin of serous cancer

  High-grade serous ovarian cancer

• 2007Fallopian tube identified as origin of high-grade serous cancer

  Ovarian cancer. Serous tubal intraepithelial carcinoma described in BRCA carriers' prophylactic specimens; leads to salpingectomy-based prevention.

  High-grade serous ovarian carcinoma (HGSOC)Risk-reducing and opportunistic salpingectomy
• 2007GOG-0161: ifosfamide-paclitaxel improves survival over ifosfamide alone

  Uterine carcinosarcoma

  IfosfamidePaclitaxel / nab-paclitaxel
• 2007Interfant-99 reports four-year event-free survival of 47 percent

  Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)

• 2007Lapatinib: first HER2 pill

  HER2-positive breast cancer

  Lapatinib
• 2007Mayo series: about 10 percent a year progress in the first five years

  Smouldering multiple myeloma

  Smouldering myeloma / MGUS
• 2007QUASAR measures the stage II benefit

  Colorectal cancer. 3,239 patients, 91 percent node-negative: relative risk of death 0.82, an absolute survival gain of about 3.6 percent.

  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study (QUASAR)
• 2007Residual cancer burden score; the relapse curve that peaks at three years

  Triple-negative breast cancer (TNBC). Symmans graded residual disease after neoadjuvant chemotherapy; Dent's Toronto cohort showed distant relapse hazard ratio 2.6 peaking at three...

  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapyTriple-negative breast cancer: clinical features and patterns of recurrenceResidual cancer burden (RCB)
• 2007Residual disease found in 46 percent of re-resections for incidental cancer

  Gallbladder cancer. Pawlik and colleagues, six centres, 115 patients: the observational basis for re-resecting T1b or deeper tumours.

  Incidence of finding residual disease for incidental gallbladder carcinoma: implications for re-resectionRadical (extended) cholecystectomy
• 2007Resistance without touching the target

  Non-small-cell lung cancer. MET amplification restores the growth signal through ERBB3 in 4 of 18 lung cancers resistant to an EGFR inhibitor, defining bypass resistance as a categ...

  MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingMET
• 2007Retrospective Italian-German study associates adjuvant mitotane with longer recurrence-free survival

  Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)

  Mitotane
• 2007ROS1 fusions identified in lung cancer

  ROS1-positive non-small-cell lung cancer

  ROS1Gene fusion
• 2007SHARP: sorafenib, the first systemic therapy

  Hepatocellular carcinoma

  SHARPSorafenib
• 2007Slotman: prophylactic cranial irradiation improves survival in extensive stage when brain imaging is not routine

  Extensive-stage small-cell lung cancer

  EORTC 08993 (Slotman): prophylactic cranial irradiation in extensive-stage small-cell lung cancerProphylactic cranial irradiation vs MRI surveillance
• 2007Sorafenib: first systemic therapy

  Hepatocellular carcinoma

• 2007Trabectedin approved in Europe for soft-tissue sarcoma

  Sarcomas (soft tissue, bone, GIST)

  Trabectedin
• 2007Trabectedin approved in Europe for soft-tissue sarcoma

  Leiomyosarcoma

  Trabectedin
• 2007Triple-negative defined as a clinical entity

  Early triple-negative breast cancer

The since year on technology records: first use in humans or first approval, as the record states it.

• 2007Bariatric surgery and cancer incidence

  First use in humans or first approval, as the technology record states it.

• 2007HER2 tyrosine kinase inhibitors

  First use in humans or first approval, as the technology record states it.

• 2007Laser interstitial thermal therapy systems (NeuroBlate, Visualase)

  First use in humans or first approval, as the technology record states it.

• 2007Visual inspection with acetic acid (VIA) for cervical screening

  First use in humans or first approval, as the technology record states it.

The founded year on company records.

• 2007Acacia Pharma founded

  Cambridge

• 2007BioAtla founded

  San Diego, California

• 2007Chinese Thoracic Oncology Group founded

  Guangzhou

• 2007P-Cure founded

  Jerusalem

• 2007Stella Pharma founded

  Osaka

• 2007Third Rock Ventures founded

  Boston, MA

The founded year on journal records.

• 2007Cell Stem Cell founded

  Cell Press (Elsevier)

• 2007Head and neck pathology founded

  Springer

• 2007Journal of cancer survivorship founded

  Springer Nature

• 2007Journal of gastrointestinal cancer founded

  Springer Nature

• 2007Molecular oncology founded

  Wiley on behalf of FEBS

• 2007The Gulf journal of oncology founded

  Gulf Federation for Cancer Control

The selected publications each biography lists, which is a reading of that person rather than a reading of the year.

• 2007Actual 10-year survival after resection of colorectal liver metastases defines cure

  JCO

• 2007Bronchoplastic surgery for non-small-cell lung cancer (in Czech)

  Rozhledy v chirurgii

• 2007Cerebral Glutamine and Glutamate Levels in Relation to Compromised Energy Metabolism: A Microdialysis Study in Subarachnoid Hemorrhage Patients

  Journal of Cerebral Blood Flow & Metabolism

• 2007Cetuximab for the treatment of colorectal cancer (CO.17)

  NEJM

• 2007Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer (TAX 323)

  NEJM

• 2007Complete Response From Thalidomide in Angiosarcoma After Treatment of Breast Cancer

  Journal of Clinical Oncology

• 2007Compressing drug development timelines in oncology using phase '0' trials

  Nature Reviews Cancer

• 2007Counting colonies of clonogenic assays by using densitometric software

  Radiation Oncology

• 2007Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled...

  Lancet

• 2007Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties

  Proceedings of the National Academy of Sciences

• 2007Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial (START)

  JCO

• 2007Free Functioning Muscle Transfer for Lower Extremity Posttraumatic Composite Structure and Functional Defect

  Plastic & Reconstructive Surgery

• 2007Genome-wide association study identifies novel breast cancer susceptibility loci

  Nature

• 2007Granular cell tumors of the urinary bladder

  World Journal of Surgical Oncology

• 2007High-resolution Computed Tomography Findings of Diffuse Pulmonary Involvement by Mycosis Fungoides

  Journal of Thoracic Imaging

• 2007History of oncolytic viruses: genesis to genetic engineering

  Molecular Therapy

• 2007Hormone replacement therapy use and variations in the risk of breast cancer

  BJOG: An International Journal of Obstetrics & Gynaecology

• 2007Human papillomavirus and cervical cancer

  Lancet

• 2007Isolation of rare circulating tumour cells in cancer patients by microchip technology

  Nature

• 2007Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials network...

  Journal of Clinical Oncology

• 2007Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors

  Nephrology Dialysis Transplantation

• 2007Long-term results after radical resections for pancreatic ductal adenocarcinoma (in Czech)

  Rozhledy v chirurgii

• 2007Long-Term Survival Associated With Complete Resection After Induction Chemotherapy in Stage IIIA (N2) and IIIB (T4N0-1) Non–Small-Cell Lung Cancer Patients: The...

  Journal of Clinical Oncology

• 2007MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  Proceedings of the National Academy of Sciences

• 2007MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer

  New England Journal of Medicine

• 2007MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer (ACRIN 6667)

  NEJM

• 2007OLFACTORY GROOVE MENINGIOMAS

  Neurosurgery

• 2007PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

  Lancet Oncology

• 2007Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy

  Blood

• 2007Programmed anuclear cell death delimits platelet life span

  Cell

• 2007Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

  Journal of Clinical Oncology

• 2007Serum VEGF-C is associated with metastatic site in patients with malignant melanoma

  Acta Oncologica

• 2007Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

  NEJM

• 2007Surgical removal of an embolised patent ductus arteriosus amplatzer occluding device in a 4-year-old girl

  Interact Cardiovasc Thorac Surg

• 2007TGF-β signaling alterations and susceptibility to colorectal cancer

  Human Molecular Genetics

• 2007Trastuzumab--mechanism of action and use in clinical practice

  New England Journal of Medicine

• 2007Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells

  Proceedings of the National Academy of Sciences